Six-week evaluator-blind randomized active-controlled study of mometasone furoate + formoterol in children with persistent asthma

Phase 2, randomised, single-blind trial of mometasone furoate + formoterol fumarate, montelukast and beclomethasone dipropionate in persistent asthma (5 arms), sponsored by Merck & Co. Primary endpoint: Mean change from baseline in log transformed plasma cortisol AUC(0-24 hours) at Day 42. Started Jun 2012; status: completed.